Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRABITAS: bi-weekly versus conventional TAS-102 plus bevacizumab for metastatic colorectal cancer
jRCTs041230120Phase 3Active, not recruiting
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trifluridine + tipiracil and bevacizumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms). Primary endpoint: Overall survival. Started Dec 2023; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCTs041230120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230120.